403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Eupraxia Pharmaceuticals Inc.
(MENAFN- Baystreet) 09:39 AM EST - Eupraxia Pharmaceuticals Inc. : Announced positive treatment outcomes from its ongoing RESOLVE Phase 1b/2a trial evaluating EP-104GI for the treatment of eosinophilic esophagitis. Most notably, nine-month data was disclosed for the first time demonstrating that all three patients dosed at 48mg of EP-104GI experienced sustained or improved treatment outcomes after nine months of therapy. Eupraxia Pharmaceuticals Inc.
shares T are trading unchanged at $5.51.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment